

DAFTAR PUSTAKA

- Affengruber, L. *et al.* (2024) ‘An exploration of available methods and tools to improve the efficiency of systematic review production : a scoping review’, *BMC Medical Research Methodology* [Preprint]. Available at: <https://doi.org/10.1186/s12874-024-02320-4>.
- Andrade, I. *et al.* (2022) ‘Fifteen years of enzyme replacement therapy for mucopolysaccharidosis type VI (Maroteaux – Lamy syndrome): a case report’, *Journal of Medical Case Reports*, pp. 1–5. Available at: <https://doi.org/10.1186/s13256-021-03240-3>.
- Barry, E.S., Merkebu, J. and Varpio, L. (2022) ‘State-of-the-art literature review methodology : A six-step approach for knowledge synthesis’, pp. 281–288. Available at: <https://doi.org/10.1007/s40037-022-00725-9>.
- Bashir, A. and Tiwari, P. (2021) ‘Enzyme replacement therapy in lysosomal acid lipase deficiency (LAL-D): a systematic literature review’, pp. 1–14. Available at: <https://doi.org/10.1177/26330040211026928>.
- Berti, G.M. *et al.* (2025) ‘The importance of a multidisciplinary approach in two tricky cases : the perfect match for Fabry disease’.
- Bolano-diaz, C. and Diaz-manera, J. (2022) ‘Therapeutic Options for the Management of Pompe Disease : Current Challenges and Clinical Evidence in Therapeutics and Clinical Risk Management’, (December).
- Bor, M. (2022) ‘A Newborn with Infantile-Onset Pompe Disease Improving after Administration of Enzyme Replacement Therapy : Case Report’, pp. 62–66.
- Burton, B.K. *et al.* (2025) ‘Long-term enzyme replacement therapy : Findings from the mucopolysaccharidosis VI clinical surveillance program after 15 years’, 145(March). Available at: <https://doi.org/10.1016/j.yimgme.2025.109135>.
- Byrne, B.J. *et al.* (2025) ‘Long - term safety and efficacy of cipaglucosidase alfa plus miglustat in individuals living with Pompe disease : an open - label phase I / II study (ATB200 - 02)’, *Journal of Neurology*, (2023), pp. 1787–1801. Available at: <https://doi.org/10.1007/s00415-023-12096-0>.
- Capelli, I. *et al.* (2025) ‘The Role of Kidney Biopsy in Fabry Disease’, pp. 1–14.
- Cetin, B. *et al.* (2024) ‘Gene and cell therapy of human genetic diseases : Recent advances and future directions’, (August), pp. 1–15. Available at: <https://doi.org/10.1111/jcmm.70056>.
- Christian, H. (2023) ‘Anatomy & Physiology : Current The Role of Molecular Biology in Understanding Genetic Diseases’, 13(1000437), pp. 13–14. Available at: <https://doi.org/10.35248/2161-0940.23.13.437>.
- Coutinho, M.F., Prata, M.J. and Alves, S. (2015) ‘Mannose-6-phosphate pathway: A review on its role in lysosomal function and dysfunction’, *Molecular Genetics and Metabolism*, 105(4), pp. 542–550. Available at:

<https://doi.org/10.1016/j.ymgme.2011.12.012>.

- Cox, T.M. *et al.* (2015) ‘Eliglustat compared with imiglucerase in patients with Gaucher ’ s disease type 1 stabilised on enzyme replacement therapy : a phase 3 , randomised , open-label , non-inferiority trial’, pp. 2355–2362. Available at: [https://doi.org/10.1016/S0140-6736\(14\)61841-9](https://doi.org/10.1016/S0140-6736(14)61841-9).
- Crivaro, A.N. *et al.* (2025) ‘International Journal of Biological Macromolecules Effective encapsulation of therapeutic recombinant enzyme into polymeric nanoparticles as a potential vehicle for lysosomal disease treatment’, 285(November 2024). Available at: <https://doi.org/10.1016/j.ijbiomac.2024.138248>.
- Deegan, P. *et al.* (2021) ‘The International Collaborative Gaucher Group GRAF (Gaucher Risk Assessment for Fracture) score : a composite risk score for assessing adult fracture risk in imiglucerase - treated Gaucher disease type 1 patients’, *Orphanet Journal of Rare Diseases*, pp. 1–15. Available at: <https://doi.org/10.1186/s13023-020-01656-6>.
- Dornelles, A.D. *et al.* (2024) ‘Efficacy and safety of enzyme replacement therapy with alglucosidase alfa for the treatment of patients with infantile-onset Pompe disease: a systematic review and metanalysis’, *Frontiers in Pediatrics*, 12(February). Available at: <https://doi.org/10.3389/fped.2024.1310317>.
- Elendu, C. *et al.* (2024) ‘Genetic factors and management strategies in aortic health : a literature review of inherited aortopathy’, (December).
- Ellison, S., Parker, H. and Bigger, B. (2023) ‘Advances in therapies for neurological lysosomal storage disorders’, *Journal of Inherited Metabolic Disease*, 46(5), pp. 874–905. Available at: <https://doi.org/10.1002/jimd.12615>.
- Erb, L. (2024) ‘Revolutionizing Healthcare : The Impact of Molecular Biology in Understanding and Treating Diseases’, 12(1), pp. 2023–2024. Available at: <https://doi.org/10.35841/2320-9585-12.1.220>.
- Feldt-rasmussen, U. *et al.* (2020) ‘Long-term efficacy and safety of migalastat treatment in Fabry disease : 30-month results from the open-label extension of the randomized , phase 3’, *Molecular Genetics and Metabolism*, 131(1–2), pp. 219–228. Available at: <https://doi.org/10.1016/j.ymgme.2020.07.007>.
- Gambello, M.J. and Li, H. (2018) ‘Current strategies for the treatment of inborn errors of metabolism’, *Journal of Genetics and Genomics*, 45(2), pp. 61–70. Available at: <https://doi.org/10.1016/j.jgg.2018.02.001>.
- Germain, D.P. and Linhart, A. (2024) ‘Pegunigalsidase alfa: a novel, pegylated recombinant alpha-galactosidase enzyme for the treatment of Fabry disease’, *Frontiers in Genetics*, 15(April). Available at: <https://doi.org/10.3389/fgene.2024.1395287>.
- Giugliani, R. *et al.* (2024) ‘Disease characteristics, effectiveness, and safety of vestronidase alfa for the treatment of patients with mucopolysaccharidosis VII in a novel, longitudinal, multicenter disease monitoring program’, *Orphanet Journal of Rare Diseases*, 19(1), pp. 1–9. Available at:

<https://doi.org/10.1186/s13023-024-03176-z>.

- Guo, L. *et al.* (2025) ‘Critical appraisal of methodological quality and completeness of reporting in Chinese social science systematic reviews with meta-analysis: A systematic review’, (January 2024). Available at: <https://doi.org/10.1002/cl2.70014>.
- Hampe, C.S. *et al.* (2021) ‘Mucopolysaccharidosis type I: Current treatments, limitations and prospects for improvement’, *Biomolecules*, 11(2), pp. 1–25. Available at: <https://doi.org/10.3390/biom11020189>.
- Henderson, M.L. *et al.* (2024) ‘Gene Therapy for Genetic Syndromes: Understanding the Current State to Guide Future Care’, (Figure 1).
- Horovitz, D.D.G. *et al.* (2021) ‘Long-term impact of early initiation of enzyme replacement therapy in 34 MPS VI patients: A resurvey study’, 133, pp. 94–99. Available at: <https://doi.org/10.1016/j.ymgme.2021.02.006>.
- Hsueh, C.Y. *et al.* (2021) ‘Hearing characteristics of infantile-onset Pompe disease after early enzyme-replacement therapy’, pp. 4–11. Available at: <https://doi.org/10.1186/s13023-021-01817-1>.
- Iourov, I.Y., Vorsanova, S.G. and Yurov, Y.B. (2019) ‘Pathway-based classification of genetic diseases’, pp. 1–5.
- Itzel, V. *et al.* (2024) ‘Lysosomal diseases and enzyme replacement therapy’.
- Jenkinson, A. and Eaton, S. (2024) ‘Pancreatic Insufficiency, Digestive Enzyme Supplementation, and Postnatal Growth in Preterm Babies’, pp. 283–287. Available at: <https://doi.org/10.1159/000535964>.
- Jovanovic, A. *et al.* (2024) ‘A systematic literature review on the health-related quality of life and economic burden of Fabry disease’, *Orphanet Journal of Rare Diseases*, 19(1). Available at: <https://doi.org/10.1186/s13023-024-03131-y>.
- Kermond-Marino, A. *et al.* (2023) ‘Population Frequency of Undiagnosed Fabry Disease in the General Population’, *Kidney International Reports*, 8(7), pp. 1373–1379. Available at: <https://doi.org/10.1016/j.ekir.2023.04.009>.
- Khan, S.A. *et al.* (2017) ‘Epidemiology of mucopolysaccharidoses’, *Molecular Genetics and Metabolism*, 121(3), pp. 227–240. Available at: <https://doi.org/10.1016/j.ymgme.2017.05.016>.
- Kishnani, P.S. *et al.* (2023) ‘Safety and efficacy of avalglucosidase alfa in individuals with infantile-onset Pompe disease enrolled in the phase 2, open-label Mini-COMET study: The 6-month primary analysis report’. Available at: <https://doi.org/10.1016/j.gim.2022.10.010>.
- Kishnani, P.S. *et al.* (2024) ‘Switching treatment to cipaglucosidase alfa plus miglustat positively affects patient-reported outcome measures in patients with late-onset Pompe disease’.
- Klein, T. *et al.* (2024) ‘BRAIN COMMUNICATIONS Small fibre neuropathy in

- Fabry disease : a human-derived neuronal in vitro disease model and pilot data', *Brain Communications*, 6(2), pp. 1–20. Available at: <https://doi.org/10.1093/braincomms/fcae095>.
- Kong, W., Lu, C. and Wang, L. (2024) 'Global birth prevalence of Pompe disease: A systematic review and meta-analysis', *Neuroscience*, 563(April), pp. 167–174. Available at: <https://doi.org/10.1016/j.neuroscience.2024.09.043>.
- Koto, Y. *et al.* (2021) 'Experiences of patients with lysosomal storage disorders treated with enzyme replacement therapy: A qualitative systematic review protocol', *JBIC Evidence Synthesis*, 19(3), pp. 702–708. Available at: <https://doi.org/10.11124/JBIES-20-00017>.
- Kuhn, A.S., Makusha, L.P. and Bokhari, S.A.J. (2020) 'Symmetric , bilateral upper and lower extremity lucent lesions in a patient with Gaucher ' s disease on enzyme replacement therapy', *Radiology Case Reports*, 15(11), pp. 2067–2070. Available at: <https://doi.org/10.1016/j.radcr.2020.08.032>.
- Kuter, D.J. *et al.* (2020) 'Blood Cells , Molecules and Diseases Open-label , expanded access study of taliglucerase alfa in patients with Gaucher disease requiring enzyme replacement therapy', *Blood Cells, Molecules and Diseases*, 82(February), p. 102418. Available at: <https://doi.org/10.1016/j.bcmd.2020.102418>.
- Leal, A.F. *et al.* (2023) 'Mucopolysaccharidoses: Cellular Consequences of Glycosaminoglycans Accumulation and Potential Targets', *International Journal of Molecular Sciences*, 24(1). Available at: <https://doi.org/10.3390/ijms24010477>.
- Lee, J. (2025) 'Understanding genetic disorders : Mechanisms , diagnosis , and emerging therapies .', 7(1), pp. 2024–2025. Available at: <https://doi.org/10.35841/aarrgs-7.1.245>.
- Malherbe, H.L., Blencowe, B.M.H. and Strong, K.L. (2023) 'A review of key terminology and definitions used for birth defects globally', *Journal of Community Genetics*, pp. 241–262. Available at: <https://doi.org/10.1007/s12687-023-00642-2>.
- Marques, A.R.A. *et al.* (2020) 'Enzyme replacement therapy with recombinant pro-CTSD (cathepsin D) corrects defective proteolysis and autophagy in neuronal ceroid lipofuscinosis', *Autophagy*, 16(5), pp. 811–825. Available at: <https://doi.org/10.1080/15548627.2019.1637200>.
- Milena, S. *et al.* (2024) 'Enzyme replacement therapy and immunotherapy lead to significant functional improvement in two children with Pompe disease : a case report', *Journal of Medical Case Reports*, pp. 1–5. Available at: <https://doi.org/10.1186/s13256-024-04638-5>.
- Muenzer, J. *et al.* (2017) 'Clinical outcomes in idursulfase-treated patients with mucopolysaccharidosis type II: 3-year data from the hunter outcome survey (HOS)', *Orphanet Journal of Rare Diseases*, 12(1), pp. 1–11. Available at: <https://doi.org/10.1186/s13023-017-0712-3>.

- Nakamura, K. *et al.* (2023) 'Effects of Agalsidase Alfa Enzyme Replacement Therapy on Left Ventricular Hypertrophy on Electrocardiogram in a Female Patient with Fabry Disease', pp. 2–5. Available at: <https://doi.org/10.1536/ihj.22-752>.
- Nguyen, Y. *et al.* (2025) 'Epidemiology of Gaucher Disease in France : Trends in Incidence , Mortality , Management , and Complications Over Three Decades', pp. 1–13. Available at: <https://doi.org/10.1002/jimd.70037>.
- Panzitt, K. and Wagner, M. (2021) 'BBA - Molecular Basis of Disease FXR in liver physiology : Multiple faces to regulate liver metabolism', *BBA - Molecular Basis of Disease*, 1867(7), p. 166133. Available at: <https://doi.org/10.1016/j.bbadis.2021.166133>.
- Papaioannou, I., Owen, J.S. and Yáñez-, R.J. (2023) 'Clinical applications of gene therapy for rare diseases : A review', (March), pp. 154–176. Available at: <https://doi.org/10.1111/iep.12478>.
- Pieroni, M. *et al.* (2021) 'Cardiac Involvement in Fabry Disease: JACC Review Topic of the Week', *Journal of the American College of Cardiology*, 77(7), pp. 922–936. Available at: <https://doi.org/10.1016/j.jacc.2020.12.024>.
- Ramaswami, U. *et al.* (2025) 'Safety and efficacy of migalastat in adolescent patients with Fabry disease : Results from ASPIRE , a phase 3b , open-label , single-arm , 12-month clinical trial , and its open-label extension', *Molecular Genetics and Metabolism*, 145(1), p. 109102. Available at: <https://doi.org/10.1016/j.ymgme.2025.109102>.
- Robinson, P.K. (2015) 'Enzymes : principles and biotechnological applications', pp. 1–41. Available at: <https://doi.org/10.1042/BSE0590001>.
- Roth, T.L. and Marson, A. (2022) 'Genetic Disease and Therapy', pp. 145–166. Available at: <https://doi.org/10.1146/annurev-pathmechdis-012419-032626>. Genetic.
- Sagara, R. *et al.* (2021) 'Long - term safety and effectiveness of velaglucerase alfa in Gaucher disease : 6 - year interim analysis of a post - marketing surveillance in Japan', *Orphanet Journal of Rare Diseases*, pp. 4–11. Available at: <https://doi.org/10.1186/s13023-021-02119-2>.
- Sarah, B. *et al.* (2022) 'Clinical efficacy of the enzyme replacement therapy in patients with late - onset Pompe disease : a systematic review and a meta - analysis', *Journal of Neurology*, 269(2), pp. 733–741. Available at: <https://doi.org/10.1007/s00415-021-10526-5>.
- Schoser, B. *et al.* (2024) '104 - week efficacy and safety of cipaglucosidase alfa plus miglustat in adults with late - onset Pompe disease : a phase III open - label', pp. 2810–2823. Available at: <https://doi.org/10.1007/s00415-024-12236-0>.
- Selvan, N. *et al.* (2021) 'Endolysosomal N-glycan processing is critical to attain the most active form of the enzyme acid alpha-glucosidase', *Journal of Biological Chemistry*, 296, p. 100769. Available at:

<https://doi.org/10.1016/j.jbc.2021.100769>.

- Sevin, C. and Deiva, K. (2021) 'Clinical Trials for Gene Therapy in Lysosomal Diseases With CNS Involvement', 8(September), pp. 0–7. Available at: <https://doi.org/10.3389/fmolb.2021.624988>.
- Shah, N. (2024) 'A Randomized Controlled Trial of the Safety and Efficacy of Systemic Enzyme Supplementation on Symptoms and Quality of Life in Patients with Idiopathic Pulmonary Fibrosis'.
- Shirley, J.L. *et al.* (2020) 'Immune Responses to Viral Gene Therapy Vectors', *Molecular Therapy*, 28(3), pp. 709–722. Available at: <https://doi.org/10.1016/j.ymthe.2020.01.001>.
- Spataro, F. *et al.* (2024) 'Two-year follow-up after drug desensitization in mucopolysaccharidosis', pp. 1–4.
- Stapleton, M. *et al.* (2018) 'Clinical presentation and diagnosis of mucopolysaccharidoses', *Molecular Genetics and Metabolism*, 125(1–2), pp. 4–17. Available at: <https://doi.org/10.1016/j.ymgme.2018.01.003>.
- Stevens, D., Milani-Nejad, S. and Mozaffar, T. (2022) 'Pompe Disease: a Clinical, Diagnostic, and Therapeutic Overview', *Current Treatment Options in Neurology*, 24(11), pp. 573–588. Available at: <https://doi.org/10.1007/s11940-022-00736-1>.
- Tardieu, M. *et al.* (2023) 'term follow- - up of 64 children with classical infantile- - onset Pompe disease since 2004 : A French real- - life observational study', (May), pp. 2828–2837. Available at: <https://doi.org/10.1111/ene.15894>.
- Taverna, S. *et al.* (2020) 'Pompe disease : pathogenesis , molecular genetics and diagnosis', 12(15), pp. 15856–15874.
- Titievsky, L. *et al.* (2022) 'Safety and effectiveness of taliglucerase alfa in patients with Gaucher disease : an interim analysis of real - world data from a multinational drug registry (TALIAS)', *Orphanet Journal of Rare Diseases*, pp. 1–11. Available at: <https://doi.org/10.1186/s13023-022-02289-7>.
- Valayannopoulos, V. *et al.* (2015) 'Open Access REVIEW BioMed Central Mucopolysaccharidosis VI', *Orphanet Journal of Rare Diseases*, 5, p. 5. Available at: <http://www.ajrd.com/content/5/1/5>.
- Veen, S.J. Van Der *et al.* (2022) 'Early start of enzyme replacement therapy in pediatric male patients with classical Fabry disease is associated with attenuated disease progression', 135, pp. 163–169. Available at: <https://doi.org/10.1016/j.ymgme.2021.12.004>.
- Vilk, S.R. *et al.* (2025) 'Safety analysis of self - administered enzyme replacement therapy using data from the Fabry Outcome and Gaucher Outcome Surveys', *Orphanet Journal of Rare Diseases*, pp. 1–13. Available at: <https://doi.org/10.1186/s13023-024-03416-2>.
- Vollebregt, A.A.M. *et al.* (2022) 'Effect of Anti-Iduronate 2-Sulfatase Antibodies in Patients with Mucopolysaccharidosis Type II Treated with Enzyme

- Replacement Therapy', *The Journal of Pediatrics*, 248, pp. 100-107.e3. Available at: <https://doi.org/10.1016/j.jpeds.2022.05.008>.
- Wang, R.Y. *et al.* (2020) 'The long-term safety and efficacy of vestronidase alfa , rhGUS enzyme replacement therapy , in subjects with mucopolysaccharidosis VII', *Molecular Genetics and Metabolism*, 129(3), pp. 219–227. Available at: <https://doi.org/10.1016/j.ymgme.2020.01.003>.
- Weinreb, N.J. *et al.* (2021) 'Gaucher disease type 1 patients from the ICGG Gaucher Registry sustain initial clinical improvements during twenty years of imiglucerase treatment', 132, pp. 100–111. Available at: <https://doi.org/10.1016/j.ymgme.2020.12.295>.
- Zhao, M. *et al.* (2021) 'Cytochrome P450 Enzymes and Drug Metabolism in Humans', pp. 1–16.
- Zheng, L. and Hong, F. (2021) 'Inhibition of PI4KIII a as a Novel Potential Approach for Gaucher Disease Treatment', *Neuroscience Bulletin*, 37(8), pp. 1234–1239. Available at: <https://doi.org/10.1007/s12264-021-00704-w>.
- Zhou, Z. *et al.* (2024) 'Analytica Chimica Acta Unlocking cell surface enzymes : A review of chemical strategies for detecting enzymatic activity', *Analytica Chimica Acta*, 1332(August), p. 343140. Available at: <https://doi.org/10.1016/j.aca.2024.343140>.